- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00648258
A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg Once Daily And Naproxen 500mg Twice Daily In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In Taiwan
December 3, 2018 updated by: Pfizer
A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg QD And Naproxen 500mg BID In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In Taiwan
To evaluate the efficacy, safety, and tolerability of valdecoxib by comparing valdecoxib 10 mg daily (QD) with naproxen 500 mg twice daily (BID) in treating the signs and symptoms of osteoarthritis (OA) of the knee or hip.
The study was designed to collect comparative information for the local population (Taiwan).
Study Overview
Study Type
Interventional
Enrollment (Actual)
130
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kaohsiung, Taiwan
- Pfizer Investigational Site
-
Taichung, Taiwan
- Pfizer Investigational Site
-
Taipei, Taiwan
- Pfizer Investigational Site
-
-
Taoyuan
-
Kweishan, Taoyuan, Taiwan
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The diagnosis of hip OA, which was having hip pain and meeting criteria for at least 2 of the following: a. Westergren erythrocyte sedimentation rate of < 20 mm/hr; b. radiographic femoral or acetabular osteophytes or c. radiographic joint space narrowing
- Knee OA diagnosis required diagnosing (by modified American College of Rheumatology criteria) OA of the knee with pain plus at least one of the following: a. Age> 50 years old, b. Stiffness < 30 minutes, c. crepitus on active motion and radiographic evidence of OA of the knee, defined as presence of osteophytes or joint space narrowing
- Symptomatic OA of the knee or hip was determined at the Baseline Visit, if the Patient's Assessment of Arthritis Pain was at least 40 mm VAS, Patient's and the Physician's Global Assessment of Arthritis was "poor" or "very poor"
Exclusion Criteria:
- Use of NSAIDs or analgesics within 2 days (within 4 days for subjects taking oxaprozin, piroxicam or full dose aspirin) before baseline arthritis assessments
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 2
|
naproxen 500 mg capsule by mouth twice daily for 6 weeks
|
Active Comparator: Arm 1
|
valdecoxib 10 mg tablet by mouth once daily for 6 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Patient's Assessment of Arthritis Pain (Osteoarthritis-Pain VAS)
Time Frame: Week 6
|
Week 6
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Western Ontario and McMaster Universities Osteoarthritis (WOMAC OA) Composite Index
Time Frame: Week 2 and Week 6
|
Week 2 and Week 6
|
WOMAC OA physical function
Time Frame: Week 2 and Week 6
|
Week 2 and Week 6
|
WOMAC OA pain index
Time Frame: Week 2 and Week 6
|
Week 2 and Week 6
|
WOMAC OA stiffness index
Time Frame: Week 2 and Week 6
|
Week 2 and Week 6
|
Patient's Assessment of Arthritis Pain (Osteoarthritis-Pain VAS)
Time Frame: Week 2
|
Week 2
|
Patient's Global Assessment of Arthritis
Time Frame: Week 2 and Week 6
|
Week 2 and Week 6
|
Physician's Global Assessment of Arthritis
Time Frame: Week 2 and Week 6
|
Week 2 and Week 6
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2003
Study Completion (Actual)
April 1, 2004
Study Registration Dates
First Submitted
March 28, 2008
First Submitted That Met QC Criteria
March 28, 2008
First Posted (Estimate)
April 1, 2008
Study Record Updates
Last Update Posted (Actual)
December 5, 2018
Last Update Submitted That Met QC Criteria
December 3, 2018
Last Verified
December 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Osteoarthritis, Knee
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Gout Suppressants
- Naproxen
- Valdecoxib
Other Study ID Numbers
- VALA-0513-141
- A3471101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Ottawa Hospital Research InstituteNot yet recruitingKnee Osteoarthritis | Hip Osteoarthritis
-
University Hospital, LilleCompleted
-
Massachusetts General HospitalNewton-Wellesley Hospital; The New England Baptist HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on valdecoxib
-
PfizerCompletedPain | Hallux ValgusUnited States
-
PfizerCompletedPain, Post-surgicalUnited States
-
PfizerCompletedPainCanada, United States, Belgium, Italy, Spain, Sweden, Colombia, Germany, Poland, Australia, Netherlands, Switzerland, Israel, Denmark, Singapore, South Africa, Ireland, United Kingdom, Czech Republic, Finland, Slovakia, Argentina, A... and more
-
Penn State UniversityPfizer; National Institutes of Health (NIH)CompletedPain | HyperalgesiaUnited States
-
PfizerCompletedPain | Sprains and Strains | SprainChile, Mexico, Argentina, Colombia, Peru
-
PfizerCompletedPain, PostoperativeKorea, Republic of, Thailand, Hong Kong, Taiwan, Singapore, New Zealand, Philippines, Australia, Malaysia
-
PfizerCompletedLow Back PainChile, Venezuela, Ecuador, Colombia, Brazil, Mexico, Argentina, Peru, Costa Rica
-
PfizerCompleted
-
University of WashingtonPfizerCompleted